A U.S. jury has returned a verdict against Takeda Pharmaceutical (TYO:4502) in the AMITIZA antitrust litigation, awarding plaintiffs $884.9 million in single damages, with portions subject to automatic trebling under U.S. antitrust law.
The case consolidates claims from wholesalers, retailers, and end payors, who alleged that a 2014 patent settlement between Takeda, Sucampo, and Par Pharmaceutical was anticompetitive, according to a statement on Tuesday.
Takeda maintains the settlement was reached through proper arms-length negotiation under the Hatch-Waxman framework and allowed Par to launch an authorized generic years before patents expired.
The company has stated it will vigorously pursue post-trial motions and an appeal, citing evidentiary and legal errors during the trial.
While the verdict is not yet enforceable, Takeda is assessing the financial provision for its fiscal 2025 statements but does not expect a material impact on its fiscal 2026 core financial forecast.